Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer By Ogkologos - April 7, 2026 264 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POLAR study Source RELATED ARTICLESMORE FROM AUTHOR Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma ESMO Welcomes the European Parliament’s (EP) Call for a Sustainable Cancer Workforce to Deliver Quality Care for Patients with Cancer ESMO Welcomes the Inclusion of Tobacco Provisions in European Parliament’s Report on Cardiovascular Diseases and Calls for Additional Measures to Prevent Cancer MOST POPULAR FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or... March 6, 2025 Mobile Care Center Brings Breast Cancer Treatment to Amish and Mennonite... December 18, 2019 Simple Hysterectomy Noninferior to Radical Hysterectomy with Respect to Pelvic Recurrence... February 29, 2024 FDA Approves Device for Treatment of Osteoid Osteoma in the Extremities December 1, 2020 Load more HOT NEWS Efficacy of ICI Combined with Chemotherapy in Patients with Advanced Penile... A coming together of minds for early detection ASCO20 Virtual Research Round Up Podcast: Head and Neck Cancer and... EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide
